Sarepta Therapeutics' brutal week continued Friday after European officials rejected the company's controversial gene therapy ...

The European Medicines Agency determined testing failed to prove Elevidys’ benefit and issued a negative opinion that could ...

Friday said that the European Medicines Agency has issued a negative opinion on the conditional marketing authorization for Elevidys, intended for ambulatory patients aged three to seven with Duchenne ...

US stocks advanced midday Monday, with the S&P 500 and Nasdaq Composite notching fresh all-time intraday highs, buoyed by ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Detailed price information for Doordash Inc Cl A (DASH-Q) from The Globe and Mail including charting and trades.

Recent discussions on X about Meta Platforms, Inc. (META) have centered around a notable upgrade by a prominent analyst firm, moving the stock's rating from underperform to hold. Many users on the ...

Principal Financial Group reduced its Adobe stake by 8.3% in Q1, selling over 57,000 shares worth $242 million. Several institutional investors also adjusted their positions, reflecting mixed market ...

The New York Times revealed the mixed opinions amongst Democratic strategists over Project 2029, which aims to create a cohesive agenda for future Democratic presidential candidates.

TNT analyst Steve Letarte on NASCAR Chicago Street Race: 'Zero margin of error' Letarte thinks Shane van Gisbergen, who won the inaugural Chicago race in 2023, is the favorite.

Why didn’t federal prosecutors charge Sean Combs with more obvious, easy-to-prove offenses? Because they can’t help themselves?

Investor Action Deadline If you purchased Sarepta securities during the Class Period and suffered losses, you have until August 25, 2025, to request the Court appoint you as lead plaintiff.